Abstract: Compositions, methods of using the compositions, and solid freeform fabrication (SFF) systems for producing three-dimensional objects are disclosed. One exemplary composition, among others, includes a basic component, an acidic component, at least one monoacrylate component, a light sensitive initiator, and a polar binder. A polymerization reaction between the at least one monoacrylate component and the light sensitive initiator occurs upon exposure to optical energy. The polar binder includes a viscosity modifier and a surface tension modifier. The polar binder is capable of stimulating a crosslinking reaction between the basic component and the acidic component.

Abstract: The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof: The invention is also directed to pharmaceutical compositions, methods of use and methods of making compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof.

Abstract: The present invention is directed to compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof: (I). The invention is also directed to pharmaceutical compositions, methods of use and methods of making compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof.

Abstract: Chemical compositions are disclosed. One exemplary composition, among others, includes: a basic component, an acidic component, at least one acrylate component, oxidizing agent, reducing agent, and a binder. The binder includes a viscosity modifier and a surface tension modifier. The binder is capable of stimulating a reaction between the basic component and the acidic component. A portion of the binder is capable of undergoing a polymerization reaction between at least one acrylate component, the oxidizing agent, and the reducing agent. The polymerization reaction being initiated by the redox reaction between the oxidizing agent and the reducing agent.

Abstract: Compositions, methods of using the compositions, and solid freeform fabrication (SFF) systems for producing three-dimensional objects are disclosed. One exemplary composition, among others, includes a basic component, an acidic component, at least one monoacrylate component, a light sensitive initiator, and a polar binder. A polymerization reaction between the at least one monoacrylate component and the light sensitive initiator occurs upon exposure to optical energy. The polar binder includes a viscosity modifier and a surface tension modifier. The polar binder is capable of stimulating a crosslinking reaction between the basic component and the acidic component.

Abstract: Chemical compositions are disclosed. One exemplary composition, among others, includes: a basic component, an acidic component, at least one acrylate component, oxidizing agent, reducing agent, and a binder. The binder includes a viscosity modifier and a surface tension modifier. The binder is capable of stimulating a reaction between the basic component and the acidic component. A portion of the binder is capable of undergoing a polymerization reaction between at least one acrylate component, the oxidizing agent, and the reducing agent. The polymerization reaction being initiated by the redox reaction between the oxidizing agent and the reducing agent.

Abstract: he present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation, particularly congestive heart failure, comprising administering to a patient in need thereof an effective amount of a compound of the formula: I or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula I, including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula I.

Abstract: The present invention is directed to compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof: (I). The invention is also directed to pharmaceutical compositions, methods of use and methods of making compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof.

Abstract: An ink-jet ink composition and a method for printing are provided which involve the use of at least one perfluorinated solvent as part or all of the vehicle of the ink-jet ink. The ink-jet ink composition evidences improved bleed control, reduced paper cockle and curl, and reduced dry time upon printing onto a print medium. The use of perfluorinated solvents reduces or even eliminates material compatibility issues between the ink and the materials comprising the pen from which the ink is ejected.

Abstract: The present invention provides a method for synthesizing indolylmaleimides by reacting an activated maleimide preferably with an optionally substituted organometallic-3-indole in the presence of a transition metal catalyst.

Abstract: Novel substituted pyrazolidinones have been found to exhibit significant binding to cholecystokinin (CCK) receptors and gastrin receptors in the brain and/or peripheral sites such as the pancreas, stomach, and ileum. The pyrazolidinones are CCK and gastrin receptor antagonists and find therapeutic application in the treatment of gastrointestinal disorders, central nervous system disorders and for appetite regulation in warm-blood vertebrates. Pharmaceutical formulations for such indications are described.

Abstract: Novel substituted pyrazolidinones have been found to exhibit significant binding to cholecystokinin (CCK) receptors and gastrin receptors in the brain and/or peripheral sites such as the pancreas, stomach, and ileum. The pyrazolidinones are CCK and gastrin receptor antagonists and find therapeutic application in the treatment of gastrointestinal disorders, central nervous system disorders and for appetite regulation in warm-blood vertebrates. Pharmaceutical formulations for such indications are described.